Trial Profile
A study to assess the efficacy and tolerability of MK-0478 (muraglitazar, also, BMS-298585) co-administered with insulin in patients with type 2 diabetes
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Muraglitazar (Primary) ; Insulin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 06 Nov 2005 New trial record.